Navigation Links
Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
Date:9/27/2013

New York, September 27, 2013 -- Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics supports a new approach: one based on the genomic signature of a tumor rather than the tissue of origin in the body.

It is well known that the emergence of cancer is a multi-step process, but because of the efforts of The Cancer Genome Atlas (TCGA), funded by the US National Institutes of Health, and other large-scale cancer genomics efforts, for the first time this process can be viewed in exquisite molecular detail, mapping mutations and other molecular events affecting any of the 20,000 genes in a human cell.

Now, two major hypotheses have been confirmed from the genomic analysis of more than 3000 samples from 12 different tumor types: a limited number of specific genetic events appear to cause most tumor subtypes and tumors can be grouped by the oncogenic signatures they contain, no matter what the tissue of origin. That these oncogenic signatures are largely independent of the particular tissue in which the cancer arises indicates that certain drug combinations may be beneficial for select patients with different types of cancer.

"In future clinical trials, we envision that patients with a certain type of endometrial cancer, for example, may be enrolled in the same trial as patients with a subtype of colorectal cancer, and that patient selection for clinical trials can be guided by cancer genomics profiling in the clinic," stated Chris Sander, one of the principal investigators of Memorial Sloan-Kettering's Genome Data Analysis Center. "This work is intended to help in the design of such trials and the development of more-personalized cancer therapies."

The ability to reveal sets of cancer-causing events in molecular detail is based on three major technical and scientific developments in the last decade. New high-throughput genomic technologies and lower operating costs have enabled the collection of genetic data from many thousands of tumors. The experience and knowledge accumulated in cancer genomics in many laboratories has taught us which of the many molecular alterations in cancer are likely to contribute to oncogenesis. Linking data and knowledge, new algorithms and methods for large data analysis in the field of computational biology provide the ability to find the proverbial needles in the haystack: to derive cancer-causing molecular genetic signatures and link them to tumor subtypes and potential therapies on the background of extremely high levels of informational noise.

The Memorial Sloan-Kettering team and their colleagues in TCGA and the International Cancer Genome Consortium plan to expand these comprehensive analyses to tens of thousands of tumor samples. A glimpse of the molecular tumor landscape in more than 13,000 tumor samples is already accessible in the cBioPortal for Cancer Genomics at http://www.cbioportal.org.

Principal authors on the study are Giovanni Ciriello, Nikolaus Schultz, and Chris Sander of the Computational Biology Center at Memorial Sloan-Kettering.

The current research was supported in part by the National Cancer Institute under award number U24 CA143840.


'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related biology news :

1. Biosignatures distinguish between tuberculosis and sarcoidosis
2. Epigenetic signatures direct the repair potential of reprogrammed cells
3. Finally mapped: The brain region that distinguishes bits from bounty
4. 100+ million mapped (and growing) records of nearly every living US species
5. Genes behind obesity mapped in large-scale study
6. Sea lamprey genome mapped with help from scientists at OU
7. Rain Man-like brains mapped at UCSF
8. Stoneflies mapped across Ohio, with implications for water quality and nature conservation
9. Signal gradients in 3-D guide stem cell behavior
10. Medboxs Marijuana Dispensing System Assists Operators in Complying with Federal Governments New Canna-Business Guidelines
11. Feline behavior experts release guidelines to improve the welfare of cats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2018)... ... 2018 , ... NanoValent Pharmaceuticals, Inc ., (NanoValent) a ... today announced the National Institute of Health (NIH) Small Business ... for two separate grants. These two grants will allow NanoValent to advance two ...
(Date:10/1/2018)... , ... October 01, 2018 , ... Paragon Biosciences CEO Jeff Aronin was ... sector and for his work bringing life-altering drugs to patients in need. Jeff’s vision has ... Approvals earned by the R&D teams now at Paragon and its portfolio companies. ...
(Date:10/1/2018)... SAN FRANCISCO (PRWEB) , ... October 01, 2018 ... ... for about 2.13 million of the nation’s elderly, stories surrounding such facilities ... the nation’s largest assisted living provider, which alleges that the chain’s “callous and ...
Breaking Biology News(10 mins):
(Date:9/28/2018)... ... 28, 2018 , ... LabRoots , the leading provider ... around the world, is excited to announce Daniel Andrade, a 22-year-old undergraduate student ... of the LabRoots Summer 2018 Textbook Scholarship, awarding him $1,000 to support him ...
(Date:9/27/2018)... ANGELES (PRWEB) , ... September 26, 2018 , ... ... device and biologics manufacturer, debuted its focus® Pedicle Screw System today at the ... Center, September 26-29. , The Nvision focus Pedicle Screw System, which ...
(Date:9/22/2018)... ... September 20, 2018 , ... ... venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s ... to empower clinical trials in the immuno-oncology (IO) space. , IO therapies ...
(Date:9/15/2018)... , ... September 14, 2018 , ... Nationally recognized public ... G. Patrick, CPA , Managing Partner of the Firm’s Nashville practice, on her appointment ... Bekaert since 2009 and was named Managing Partner of the Firm’s Nashville practice ...
Breaking Biology Technology: